指南与共识前列腺癌

中危前列腺癌主动监测推荐:放射肿瘤科医生与泌尿外科医生的全国调查结果

Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
指南 / 共识 · Eur Urol Oncol · 2018-08-31

2017年1月至7月对美国915名放射肿瘤科医生和940名泌尿外科医生进行全国调查,评估其对中危前列腺癌主动监测的看法与推荐。总体应答率37.3%(n=692),两种专科对主动监测有效性认可有限,且很少为年轻中危患者推荐主动监测。

要点

  • 放射肿瘤科医生与泌尿外科医生对主动监测有效性的认可率分别为33.0%和39.8%,组间差异未达统计学显著(p=0.06)。
  • 对推荐主动监测感到自在的比例,泌尿外科医生37.6% vs 放射肿瘤科医生25.9%(p=0.001)。
  • 对于55岁健康中危前列腺癌患者,仅2.8%的放射肿瘤科医生和4.3%的泌尿外科医生推荐主动监测。

核心结论

  • 全国调查显示,许多放射肿瘤科医生和泌尿外科医生不认为主动监测有效,也不自在推荐主动监测或将其作为年轻中危前列腺癌患者的选择。

研究设计与样本

  • 2017年1月至2017年7月对美国915名放射肿瘤科医生和940名泌尿外科医生进行全国调查。
  • 主要结局为对主动监测有效性的认知、推荐主动监测的自在程度及基于病例呈现的主动监测推荐。
  • 采用Pearson卡方检验和多变量逻辑回归分析识别与主要结局相关的医生特征。

主要发现

  • 总体应答率为37.3%(n=692),放射肿瘤科医生与泌尿外科医生应答率相似(35.7% vs 38.7%;p=0.18)。
  • 认为主动监测有效的比例,泌尿外科医生39.8% vs 放射肿瘤科医生33.0%(p=0.06)。
  • 对推荐主动监测感到自在的比例,泌尿外科医生37.6% vs 放射肿瘤科医生25.9%(p=0.001)。
  • 对于55岁健康、PSA 8ng/ml、Gleason 3+4的前列腺癌患者,推荐主动监测的比例,放射肿瘤科医生2.8% vs 泌尿外科医生4.3%(调整比值比[AOR] 0.42;p=0.12)。
  • 对于75岁健康、具有相同临床病理特征的患者,推荐主动监测的比例,放射肿瘤科医生29.0% vs 泌尿外科医生35.4%(AOR 0.68;p=0.09)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括本调查的应答率适中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While active surveillance (AS) for intermediate-risk prostate cancer (PCa) remains controversial, perceptions of AS and treatment recommendations among PCa specialists are largely unknown. Thus, we performed a national survey of radiation oncologists (ROs) and urologists (UROs) to elicit attitudes and AS recommendations for intermediate-risk PCa. OBJECTIVE: To determine whether AS for PCa is becoming readily accepted by PCa specialists in the USA. DESIGN, SETTING, AND PARTICIPANTS: From January to July 2017, we conducted a national survey of 915 ROs and 940 UROs on perceptions of AS and its use among patients with intermediate-risk PCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Perceived effectiveness and comfort with AS and recommendation of AS from case presentations represented the primary outcomes. Pearson chi-square and multivariable logistic regression analyses were used to identify physician characteristics associated with primary outcomes. RESULTS AND LIMITATIONS: Overall, the response rate was 37.3% (n=692) and was similar for ROs and UROs (35.7% vs 38.7%; p=0.18). For intermediate-risk PCa, both UROs and ROs expressed limited favorable views that AS is effective (39.8% vs 33.0%; p=0.06) and felt comfortable recommending it (37.6% vs 25.9%; p=0.001). From clinical scenarios, both specialties infrequently recommended AS for a healthy patient diagnosed with intermediate-risk PCa. For a healthy 55-yr-old patient with PSA of 8ng/ml and Gleason 3+4 PCa, few ROs and UROs recommended AS (2.8% vs 4.3%; adjusted odds ratio [AOR] 0.42; p=0.12). AS was more likely to be recommended equally by ROs and UROs for a healthy 75-yr-old with the same clinicopathologic characteristics (29.0% vs 35.4%; AOR 0.68; p=0.09). Limitations include a modest response rate for our survey. CONCLUSIONS: Our national survey revealed that many ROs and UROs do not believe that AS is effective or feel comfortable recommending it or selecting it as an option for younger patients with intermediate-risk PCa. PATIENT SUMMARY: We performed a national survey of radiation oncologists and urologists to assess attitudes regarding active surveillance (AS) and its use among patients with intermediate-risk prostate cancer. Our study demonstrates that radiation oncologists and urologists are not yet comfortable with recommending AS and rarely endorse its use for younger patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SP, Shah ND, Meropol NJ, et al. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2018. PMID: 31017095. doi:10.1016/j.euo.2018.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。